ChiCTR2200056432 版本V1.3 版本创建时间2022/09/30 15:06:29 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200056432 

最近更新日期:

Date of Last Refreshed on:

2022-09-30 15:04:01 

注册时间:

Date of Registration:

2022-02-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

外周血自然杀伤细胞升高及其治疗对不明原因反复种植失败患者妊娠结局的影响研究

Public title:

Effect of elevated peripheral blood natural killer cells on pregnancy outcome in patients with unexplained repeated implantation failure

注册题目简写:

English Acronym:

研究课题的正式科学名称:

外周血自然杀伤细胞升高及其治疗对不明原因反复种植失败患者妊娠结局的影响研究

Scientific title:

Effect of elevated peripheral blood natural killer cells and its treatment on pregnancy outcome in patients with unexplained repeated implantation failure

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曾中虹 

研究负责人:

杨一华 

Applicant:

Zhonghong Zeng 

Study leader:

Yihua Yang 

申请注册联系人电话:

Applicant telephone:

15185198353

研究负责人电话:

Study leader's
telephone:

0771-5356816

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2959298708@qq.com

研究负责人电子邮件:

Study leader's E-mail:

workyyh@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广西医科大学第一附属医院广西生殖医学研究中心

研究负责人通讯地址:

广西医科大学第一附属医院广西生殖医学研究中心

Applicant address:

Guangxi Reproductive Medical Center, the First Affiliated Hospital of Guangxi Medical University

Study leader's address:

Guangxi Reproductive Medical Center, the First Affiliated Hospital of Guangxi Medical University

申请注册联系人邮政编码:

Applicant postcode:

530021

研究负责人邮政编码:

Study leader's postcode:

530021

申请人所在单位:

广西医科大学第一附属医院广西生殖医学研究中心

Applicant's institution:

Guangxi Reproductive Medical Center, the First Affiliated Hospital of Guangxi Medical University

研究负责人所在单位:

广西医科大学第一附属医院广西生殖医学研究中心

Affiliation of the Leader:

Guangxi Reproductive Medical Center, the First Affiliated Hospital of Guangxi Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021(KY-E-303),2021-008

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广西医科大学第一附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First Affiliated Hospital of Guangxi Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-12-04 00:00:00

伦理委员会联系人:

刘老师

Contact Name of the ethic committee:

Teacher Liu

伦理委员会联系地址:

广西医科大学第一附属医院科研部

Contact Address of the ethic committee:

Research Department of the First Affiliated Hospital of Guangxi Medical University

伦理委员会联系人电话:

Contact phone of the ethic committee:

0771 5356557

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gxmuyfyll@163.com

研究实施负责(组长)单位:

广西医科大学第一附属医院广西生殖医学研究中心

Primary sponsor:

Guangxi Reproductive Medical Center, the First Affiliated Hospital of Guangxi Medical University

研究实施负责(组长)单位地址:

广西医科大学第一附属医院广西生殖医学研究中心

Primary sponsor's address:

Guangxi Reproductive Medical Center, the First Affiliated Hospital of Guangxi Medical University

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广西

市(区县):

南宁

Country:

China

Province:

Guangxi

City:

Nanning

单位(医院):

广西医科大学第一附属医院广西生殖医学研究中心

具体地址:

青秀区双拥路6号

Institution
hospital:

Guangxi Reproductive Medical Center, the First Affiliated Hospital of Guangxi Medical University

Address:

6 Shuangyong Road, Qingxiu District

经费或物资来源:

国家自然科学基金,广西自然科学基金

Source(s) of funding:

National Natural Science Foundation of China ,Natural Science Foundation of Guangxi Zhuang Autonomous Region

研究疾病:

不明原因反复种植失败  

Target disease:

Unexplained Recurrent Implantation Failure

研究疾病代码:

Target disease code:

研究类型:

治疗研究

Study type:

Treatment study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

确定外周血自然杀伤细胞浓度及其治疗对不明原因RIF患者妊娠结局的影响,提高RIF患者的活产率。  

Objectives of Study:

To determine the effect of peripheral blood natural killer cell concentration and its treatment on pregnancy outcome of patients with unexplained RIF, to improve the live birth rate of patients with RIF.

药物成份或治疗方案详述:

本研究回顾性分析不明原因反种植失败(URIF)患者外周血自然杀伤细胞(pNKC)检查和治疗结局,根据其在外周血淋巴细胞的占比分为两组:正常pNKC组(<18%),高pNKC组(≥18%),行胚胎移植后观察两组患者的胚胎种植率、临床妊娠率、流产率及活产率,以确定不同pNKC浓度对URIF患者妊娠结局的影响。后期将两组分为口服糖皮质激素与对照组(不使用糖皮质激素),观察胚胎移植后患者的胚胎种植率、临床妊娠率、流产率及活产率,明确糖皮质激素对是否可改善URIF的妊娠结局,妊娠结局的改善是否与pNKC的浓度有关。 

Description for medicine or protocol of treatment in detail:

In this study, peripheral blood natural killer cells (pNKC) were examined in patients with unexplained implantation failure (uRIF). According to their proportion in peripheral blood lymphocytes, they were divided into two groups: normal pNKC group (< 18%) and high pNKC group (≥ 18%). After embryo transfer, the embryo implantation rate, clinical pregnancy rate, abortion rate and live birth rate of the two groups were observed, to determine the effect of different pNKC concentrations on pregnancy outcome in uRIF patients. Later, the two groups were divided into oral glucocorticoids and control group (without glucocorticoids). The embryo implantation rate, clinical pregnancy rate, abortion rate and live birth rate of patients after embryo transfer were observed to determine whether glucocorticoids can improve the pregnancy outcome of uRIF and whether the improvement of pregnancy outcome is related to the concentration of pNKC. 

纳入标准:

1. 年龄20-40岁;
2. 诊断为不明原因反复种植失败;
3. 男女双方染色体正常。

Inclusion criteria

1. Age 20-40 years;
2. Diagnosed as URIF;
3. The chromosomes of spouse are normal;

排除标准:

1. 患者拒绝签署知情同意书;
2. 黄体功能不全、甲状腺功能异常、糖尿病、催乳素腺瘤及自身免疫性疾病患者;
3. B超下可见的双侧输卵管积水未行结扎患者;
4. 生殖道畸形、慢性子宫内膜炎患者;
5. 合并子宫内膜异位症,子宫肌瘤,宫腔粘连 (包括既往宫腔粘连分离术) 患者
6. 血栓前状态患者;
7. 移植当月行内膜搔刮,宫腔灌注患者;
8. 吸烟、酗酒、饮用过量咖啡、滥用药物等不良嗜好患者;
9. 不良环境因素,例如有害化学物质的过多接触、放射线的过量暴露等;
10. 对药物泼尼松有严重速发性过敏。

Exclusion criteria:

1. Patients refused to sign the informed consent form;
2. Patients with luteal insufficiency, abnormal thyroid function, diabetes, prolactinoma and autoimmune diseases;
3. Patients with bilateral hydrosalpinx visible under ultrasound without ligation;
4. Patients with genital tract malformations and chronic endometritis;
5. Patients with endometriosis, uterine fibroids, intrauterine adhesions (including previous intrauterine adhesion separation)
6. Patients with prethrombotic state;
7. Patients weith endometrial scraping and intrauterine perfusion in the embryo transfer cycle;
8. Patients with bad habits such as smoking, alcohol abuse, excessive coffee drinking, drug abuse, etc.
9. Unfavorable environmental factors, such as excessive exposure to harmful chemical substances, excessive exposure to radiation, etc.
10.Severe immediate allergy to the drug prednisone.

研究实施时间:

Study execute time:

From 2022-03-01 00:00:00 To 2022-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-03-01 00:00:00 To 2022-05-01 00:00:00

干预措施:

Interventions:

组别:

pNKC升高与pNKC正常组

样本量:

100

Group:

high pNKC and normal pNKC group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

pNKC升高口服泼尼松组

样本量:

150

Group:

High pNKC with oral prednisone treatment group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

pNKC正常组

样本量:

150

Group:

Normal pNKC with oral prednisone treatment group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广西 

市(区县):

南宁市 

Country:

China

Province:

Guangxi

City:

Nanning

单位(医院):

广西医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Guangxi Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广西 

市(区县):

 

Country:

China

Province:

Guangxi

City:

单位(医院):

柳州市妇幼保健院 

单位级别:

三级甲等 

Institution
hospital:

Liuzhou Municipal Maternity and Child Healthcare Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

活产率

指标类型:

主要指标

Outcome:

Live birth rate

Type:

Primary indicator

测量时间点:

分娩后

测量方法:

电话随访

Measure time point of outcome:

After delivery

Measure method:

Telephone follow-up

指标中文名:

临床妊娠率

指标类型:

次要指标

Outcome:

Clinical pregnancy rate

Type:

Secondary indicator

测量时间点:

胚胎移植术后14天

测量方法:

阴道B超

Measure time point of outcome:

14 days after embryo transfer

Measure method:

Transvaginal ultrasound

指标中文名:

流产率

指标类型:

次要指标

Outcome:

Abortion rate

Type:

Secondary indicator

测量时间点:

孕28周前

测量方法:

电话随访

Measure time point of outcome:

Before 28 weeks of gestation

Measure method:

Telephone follow-up

指标中文名:

胚胎种植率

指标类型:

次要指标

Outcome:

Embryo implantation rate

Type:

Secondary indicator

测量时间点:

胚胎移植术后35天

测量方法:

阴道B超

Measure time point of outcome:

35 days after embryo transfer

Measure method:

Transvaginal ultrasound

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 40 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

为回顾性病例分析,非随机对照研究。

Randomization Procedure (please state who generates the random number sequence and by what method):

A non randomized controlled study was conducted for retrospective case analysis.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No data sharing

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF由广西医科大学第一附属医院和柳州妇幼保健院生殖中心统一保存和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All the data in CRFs are preserved and managed by The First Affiliated Hospital of Guangxi Medical University and Liuzhou Maternal and Child Health Care Hospital

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-02-06 10:20:09